Klaus Elenius

11.9k total citations · 1 hit paper
105 papers, 6.2k citations indexed

About

Klaus Elenius is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Klaus Elenius has authored 105 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Molecular Biology, 54 papers in Oncology and 26 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Klaus Elenius's work include HER2/EGFR in Cancer Research (42 papers), Monoclonal and Polyclonal Antibodies Research (23 papers) and Lung Cancer Treatments and Mutations (16 papers). Klaus Elenius is often cited by papers focused on HER2/EGFR in Cancer Research (42 papers), Monoclonal and Polyclonal Antibodies Research (23 papers) and Lung Cancer Treatments and Mutations (16 papers). Klaus Elenius collaborates with scholars based in Finland, United States and United Kingdom. Klaus Elenius's co-authors include Markku Jalkanen, Maria Sundvall, Teemu T. Junttila, Markku Salmivirta, Jorma Isola, Michael Klagsbrun, Kari J. Kurppa, Minna Tanner, Maija Hollmén and Heikki Joensuu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Circulation.

In The Last Decade

Klaus Elenius

103 papers receiving 6.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab

2005 545 citations Minna Tanner, Teemu T. Junttila et al. profile →

Peers

Klaus Elenius

ONCOL

RNMI

PRM

Jacob Pe’er Israel

D. J. Ruiter Netherlands

Naomi Fukai United States

Gary D. Shipley United States

Françoise Rédiní France

Alexander Berndt Germany

Bronislaw Pytowski United States

Lone Rønnov‐Jessen Denmark

Mats Hellström Sweden

Pamela F. Jones United Kingdom

Jacob Pe’er Israel

Klaus Elenius

3.6k ×1.1

1.8k ×0.7

ONCOL

500 ×0.4

1.5k ×1.3

RNMI

658 ×0.7

PRM

Citations per year, relative to Klaus Elenius Klaus Elenius (= 1×) peers Jacob Pe’er

Countries citing papers authored by Klaus Elenius

Since Specialization

Citations

This map shows the geographic impact of Klaus Elenius's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaus Elenius with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaus Elenius more than expected).

Fields of papers citing papers by Klaus Elenius

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaus Elenius. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaus Elenius. The network helps show where Klaus Elenius may publish in the future.

Co-authorship network of co-authors of Klaus Elenius

This figure shows the co-authorship network connecting the top 25 collaborators of Klaus Elenius. A scholar is included among the top collaborators of Klaus Elenius based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klaus Elenius. Klaus Elenius is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vogt, Andreas, Ilkka Paatero, Klaus Elenius, et al.. (2024). DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer. EMBO Molecular Medicine. 16(7). 1603–1629. 9 indexed citations

Ruzicka, Regina, Laura L. Elo, Mark S. Johnson, et al.. (2022). An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations. Cancer Research Communications. 2(1). 10–27. 2 indexed citations

Kurppa, Kari J., et al.. (2021). Structural Basis for the Functional Changes by EGFR Exon 20 Insertion Mutations. Cancers. 13(5). 1120–1120. 12 indexed citations

Kurppa, Kari J., et al.. (2020). Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation. Journal of Visualized Experiments. 5 indexed citations

Kurppa, Kari J., et al.. (2020). Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation. Journal of Visualized Experiments. 4 indexed citations

Paatero, Ilkka, et al.. (2013). CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro. Gynecologic Oncology. 129(1). 179–187. 23 indexed citations

Peippo, Maarit, et al.. (2012). Translation of a Research-Based Genetic Test on a Rare Syndrome into Clinical Service Testing, with Sotos Syndrome As an Example. Genetic Testing and Molecular Biomarkers. 16(10). 1188–1194. 3 indexed citations

Veikkolainen, Ville, Florence Naillat, Antti Railo, et al.. (2011). ErbB4 Modulates Tubular Cell Polarity and Lumen Diameter during Kidney Development. Journal of the American Society of Nephrology. 23(1). 112–122. 38 indexed citations

Sundvall, Maria, Ville Veikkolainen, Kari J. Kurppa, et al.. (2010). Cell Death or Survival Promoted by Alternative Isoforms of ErbB4. Molecular Biology of the Cell. 21(23). 4275–4286. 49 indexed citations

10.

Muraoka-Cook, Rebecca S., Melissa Sandahl, Karen E. Strunk, et al.. (2009). ErbB4 Splice Variants Cyt1 and Cyt2 Differ by 16 Amino Acids and Exert Opposing Effects on the Mammary Epithelium In Vivo. Molecular and Cellular Biology. 29(18). 4935–4948. 63 indexed citations

11.

Aqeilan, Rami I., Valentina Donati, Eugenio Gaudio, et al.. (2007). Association of Wwox with ErbB4 in Breast Cancer. Cancer Research. 67(19). 9330–9336. 95 indexed citations

12.

Erjala, Kaisa, Na Zhang, Maria Sundvall, et al.. (2007). Concomitant chemoirradiation with vinorelbine and gefitinib induces additive effect in head and neck squamous cell carcinoma cell lines in vitro. Radiotherapy and Oncology. 85(1). 138–145. 6 indexed citations

13.

Muraoka-Cook, Rebecca S., et al.. (2006). The Intracellular Domain of ErbB4 Induces Differentiation of Mammary Epithelial Cells. Molecular Biology of the Cell. 17(9). 4118–4129. 71 indexed citations

14.

Junttila, Teemu T., Maria Sundvall, Mikael Lundin, et al.. (2005). Cleavable ErbB4 Isoform in Estrogen Receptor–Regulated Growth of Breast Cancer Cells. Cancer Research. 65(4). 1384–1393. 159 indexed citations

15.

Junttila, Teemu T., et al.. (2005). Neuregulin-1 stimulates angiogenesis via paracrine up-regulation of VEGF-A expression. Cancer Research. 65. 911–911. 1 indexed citations

16.

Tanner, Minna, Anita I. Kapanen, Teemu T. Junttila, et al.. (2004). Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Molecular Cancer Therapeutics. 3(12). 1585–1592. 214 indexed citations

17.

Junttila, Teemu T., Matti Laato, Tero Vahlberg, et al.. (2003). Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients.. PubMed. 9(14). 5346–57. 92 indexed citations

18.

Jalkanen, Markku, Klaus Elenius, & Alan C. Rapraeger. (1993). Syndecan: Regulator of Cell Morphology and Growth Factor Action at the Cell-matrix Interface.. Trends in Glycoscience and Glycotechnology. 5(22). 107–120. 23 indexed citations

19.

Salmivirta, Markku, Heikki Rauvala, Klaus Elenius, & Markku Jalkanen. (1992). Neurite growth-promoting protein (amphoterin, p30) binds syndecan. Experimental Cell Research. 200(2). 444–451. 85 indexed citations

20.

Elenius, Klaus. (1992). Growth factors induce 3T3 cells to express bFGF-binding. Journal of Biological Chemistry. 25. 6435–6441. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact